Venture firms exit PowderMed in Pfizer deal

Global pharmaceuticals group Pfizer paid a reported $400m to acquire PowderMed, a UK DNA-vaccines company backed by Advent Venture Partners, Abingworth Management, Oxford Bioscience Partners and SV Life Sciences.